MLYS
Mineralys Therapeutics, Inc. Common Stock
NASDAQ: MLYS · HEALTHCARE · BIOTECHNOLOGY
$25.56
-1.27% today
Updated 2026-04-29
Market cap
$2.11B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.29
Dividend yield
—
52W range
$13 – $48
Volume
1.2M
Mineralys Therapeutics, Inc. Common Stock (MLYS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | $43000.00 | $59000.00 |
| Gross profit | — | — | — | — | $-43000.00 | $-59000.00 |
| Gross margin | — | — | — | — | — | — |
| R&D | $2.41M | $16.31M | $26.25M | $70.36M | $168.58M | $132.01M |
| SG&A | $532000.00 | $2.42M | $5.23M | $14.30M | $23.82M | $38.59M |
| Operating income | $-2.94M | $-18.73M | $-31.48M | $-84.66M | $-192.40M | $-170.60M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-3.31M | $-19.38M | $-31.48M | $-84.66M | $-192.36M | $-170.60M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-5.89M | $-37.45M | $-31.48M | $-84.82M | $-192.40M | $-170.66M |
| Interest expense | $115000.00 | $27000.00 | $1.68M | — | — | — |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-3.43M | $-19.41M | $-29.80M | $-71.90M | $-177.81M | $-154.65M |
| Net income growth (YoY) | — | -466.5% | -53.5% | -141.3% | -147.3% | +13.0% |
| Profit margin | — | — | — | — | — | — |